Antimicrobial and Biocompatible Endotracheal Tubes

呼吸机相关性肺炎（VAP）发生在以下48-72小时（或更长时间） 气管内插管，占所有医院获得性 肺炎CDC报告和许多临床研究指出， 预防呼吸机相关感染，而不是打一场经常失败的战斗 防止后天感染为了应对这一未满足的需求，WynnVision LLC，“WV”将 利用抗微生物但细胞相容性（ABC）纳米 在制造的插管产品上添加涂层，以开发一种新技术， 消除或大大减少VAP/VAE。西弗吉尼亚州的做法，受到最近的保护， 专利申请，将涉及多学科活动和第三方测试， 便于接近FDA获得批准。

Ventilator-associated pneumonia (VAP) occurs 48–72 hours (or more) following endotracheal intubation and accounts for half of all cases of hospital-acquired pneumonia. CDC reports and many clinical studies point to a critical need for preventing ventilator associated infections rather than fighting an often losing battle against acquired infection. Responding to this unmet need, WynnVision LLC, “WV” will leverage strong preliminary results for antimicrobial-but-cytocompatible (ABC) nano- overcoats on as-manufactured intubation products to develop a new technology for eliminating or greatly reducing VAP/VAE. The WV approach, protected by a recent patent application, will involve multidisciplinary activities and third party testing to facilitate approaching FDA for approval.